Flagship Ventures

About The Fund

Flagship Ventures, known as Flagship Pioneering, is a venture capital fund that operates with a focus on fostering innovation within the biotechnology, agricultural technology, clean technology, food and beverage, medical devices and hospital services, healthcare and wellness, and pharmaceuticals and medicine industries. The fund is distinctive for its pioneering approach to venture creation, leveraging their unique process to systematize innovation and produce breakthrough companies. Their investment thesis is deeply rooted in supporting ventures from the earliest stages of ideation through growth phases which include seed, Series A through to Series B, and pre-seed rounds. They are prepared to invest between $100,000 to $5,000,000, with a sweet spot of roughly $1,500,000 for investments that align with their vision. With assets under management totaling approximately $824,000,000, they have a robust capacity to foster the development of cutting-edge companies and technologies. Flagship Ventures is involved in creating and investing in companies like Moderna and other notable ventures in the life sciences sphere. The firm's methodology is designed to recognize and support pioneering startups that can lead to important advances in health and sustainability. Through their various initiatives and programs such as Pioneering Medicines and Flagship Fellowship, Flagship Pioneering encourages and supports the creation of impactful and transformative companies. The firm's managing partner, Doug Cole, contributes his expertise from a background in neurology and active roles in both medical practice and the biotechnology industry. Throughout their portfolios, Flagship Pioneering demonstrates a deep commitment to using science and innovation to address some of today's most pressing challenges in health and medicine, reflecting their goals in their investments and the strategic guidance provided to their portfolio companies.